Advancing Accuracy in Chronic Kidney Disease Diagnosis and Management: Reference Materials and Reference Measurement Procedures for Clinical Markers
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Chronic kidney disease (CKD) is a major non-communicable disease and a leading cause of mortality worldwide. With the increasing prevalence of risk factors such as diabetes mellitus, obesity, and hypertension in the 21st century, CKD currently affects over 10% of the global population. The clinical and economic burden of this widespread disease is pro- jected to continue to rise worldwide. Early detection, treatment, and monitoring of this pro- gressive condition through accurate clinical laboratory testing of CKD biomarkers are para- mount to mitigate this growing healthcare challenge. The development of reference mate- rials (RMs) and reference measurement procedures (RMPs) for these clinical analytes is pivotal to ensuring accurate measurements using in vitro diagnostics. In this review, we emphasize the importance of establishing RMs and RMPs to standardize the measure- ments of key clinical markers for CKD, i.e., urine and serum creatinine, urine albumin, se- rum cystatin C, and urea. Standardizing CKD biomarker measurements based on RMs and RMPs can help support global efforts to reduce CKD-related morbidity and healthcare costs by ensuring reliable diagnostic practices.
Abstract
Chronic kidney disease (CKD) is a major non-communicable disease and a leading cause of mortality worldwide. With the increasing prevalence of risk factors such as diabetes mellitus, obesity, and hypertension in the 21st century, CKD currently affects over 10% of the global population. The clinical and economic burden of this widespread disease is pro- jected to continue to rise worldwide. Early detection, treatment, and monitoring of this pro- gressive condition through accurate clinical laboratory testing of CKD biomarkers are para- mount to mitigate this growing healthcare challenge. The development of reference mate- rials (RMs) and reference measurement procedures (RMPs) for these clinical analytes is pivotal to ensuring accurate measurements using in vitro diagnostics. In this review, we emphasize the importance of establishing RMs and RMPs to standardize the measure- ments of key clinical markers for CKD, i.e., urine and serum creatinine, urine albumin, se- rum cystatin C, and urea. Standardizing CKD biomarker measurements based on RMs and RMPs can help support global efforts to reduce CKD-related morbidity and healthcare costs by ensuring reliable diagnostic practices.